鉄欠乏性貧血の世界市場（2025年～2032年）

世界の鉄欠乏性貧血の市場規模は、2024年に43億9,000万米ドルに達し、2032年には73億3,000万米ドルに達すると予測され、予測期間2025年～2032年のCAGRは6.8%で成長する見込みです。

世界の鉄欠乏性貧血（IDA）市場には、体内の鉄量不足を特徴とする鉄欠乏性貧血の診断、治療、管理に特化した分野が含まれます。この鉄欠乏は、ヘモグロビン産生の低下や全身への酸素運搬障害につながります。この市場には、この広範な健康問題に対処することを目的とした、経口および非経口鉄サプリメント、診断ツール、ヘルスケアサービスなどの様々な治療法が含まれます。

鉄欠乏性貧血は、酸素運搬を担う赤血球中のタンパク質であるヘモグロビンを十分に産生するための鉄が体内で不足した場合に生じます。この状態は、疲労、脱力感、青白い肌、息切れなどの症状として現れます。ヘモグロビン欠乏症は、生殖年齢の女性、子ども、慢性疾患を持つ人など、社会的弱者に特に多く見られます。これらの要因が、世界の鉄欠乏性貧血市場拡大の原動力となっています。

市場力学：

促進要因と抑制要因

鉄欠乏性貧血の有病率の増加

鉄欠乏性貧血（IDA）の有病率の増加は、世界の鉄欠乏性貧血市場の重要な促進要因となっており、その成長と進化に影響を与えています。食事からの鉄摂取不足は、依然としてIDAの主な原因となっています。特に開発途上地域では、多くの人々が鉄分の豊富な食品を入手できず、貧血の症例が増加しています。鉄源を優先しない貧しい食習慣は、さらに貧血の蔓延を助長しています。

2022年1月の国立生物工学情報センター（NCBI）の調査データによると、世界保健機関（WHO）は、世界的に最も蔓延している栄養欠乏症として鉄欠乏性貧血（IDA）を認識しており、人口の約30％が罹患しています。IDAは特に小児や女性に多くみられますが、成人男性も、特に社会経済的地位や健康状態によってはリスクがあります。

IDAの主な原因としては、女性では消化管（GI）出血や月経が挙げられますが、食事からの鉄摂取量や吸収率の低下もまた、IDAに大きく関与しています。IDAは世界人口のかなりの部分に影響を及ぼしており、2021年には約19億2,000万人が貧血状態にあると推定されています。これには、特にサハラ以南のアフリカや南アジアのような地域における、生殖年齢の女性や幼児における顕著な有病率が含まれます。

さらに、業界の主要機関による取り組みと製品発売が、世界の鉄欠乏性貧血市場の成長を促進しています。例えば、2022年11月、ケララ州政府は、ヘモグロビン（Hb）レベルを12mg/dLに維持することを目的とした包括的な計画を策定することにより、女性の鉄欠乏性貧血（IDA）に対処するための重要な対策を実施しました。このイニシアチブは、インドの15～49歳の女性の約57％が貧血であり、農村部ではさらに高い割合であることが明らかになった、全国家族健康調査（NFHS-5）の懸念すべき調査結果に対応するものです。

また、2023年6月、米国食品医薬品局（FDA）は、心不全の成人患者における鉄欠乏の治療薬として、インジェクタファーとして販売されているカルボキシマルトース第二鉄注射剤を承認しました。この承認は、インジェクタファーが、この患者集団に特に適応のある最初で唯一の静脈内（IV）鉄補充療法として確立されたことを意味し、特に重要です。これらすべての要因が、世界の鉄欠乏性貧血市場に需要をもたらしています。

さらに、未開拓の新興市場の成長に対する需要の高まりも、世界の鉄欠乏性貧血市場の拡大に寄与しています。

治療に伴う副作用

鉄欠乏性貧血（IDA）は世界の健康上の大きな課題であり、その治療市場は様々な要因、特に治療オプションに伴う副作用によって形成されています。これらの副作用を理解することは、患者のコンプライアンスを改善し、効果的な治療戦略を確保するために不可欠です。

経口鉄剤は広く使用されていますが、その有効性を制限する消化器系の副作用につながることが多いです。一般的な副作用には、吐き気、便秘、下痢、腹部不快感、色の濃い便などがあります。このような消化器系の問題は服薬アドヒアランスを低下させる一因となり、最大50％の患者がこのような副作用のために治療を中断する可能性があることが研究で示されています。

カルボキシマルトース鉄剤やスクロース鉄剤などの静注鉄剤は、経口鉄剤に不耐容の患者の代替療法となります。アレルギー反応はまれではあますが、管理された環境での投与が必要となります。従って、上記の要因が鉄欠乏性貧血の世界市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 鉄欠乏性貧血の有病率の増加
  • 抑制要因
    • 治療に伴う副作用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 治療タイプ別

• 経口鉄療法
  • 硫酸鉄
  • グルコン酸鉄
  • フマル酸第一鉄
  • 多糖類鉄複合体
• 非経口鉄療法
  • カルボキシマルトース鉄
  • フェルモキシトール
  • 鉄スクロース
  • 鉄デキストラン
• 赤血球輸血
• その他

第7章 年齢層別

• 成人
• 小児
• 高齢者

第8章 エンドユーザー別

• 病院
• 専門クリニック
• 在宅ケア設定

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• Daiichi Sankyo, Inc.
  • 会社概要
  • 製品ポートフォリオ
    • 製品説明
    • 製品の主要業績評価指標（KPI）
    • 実績および予測の製品販売
    • 製品販売量
  • 財務概要
    • 企業収益
    • 地域別収益分配
    • 収益予測
  • 主な発展
    • 合併と買収
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• Covis Pharma GmbH.
• Akebia Therapeutics, Inc.
• PHARMACOSMOS A/S
• AbbVie.
• Shield Therapeutics plc
• GSK plc
• Rockwell Medical, Inc.
• Kye Pharmaceuticals, Inc.
• Cadila Pharmaceuticals

第12章 付録

The global iron deficiency anemia market reached US$ 4.39 billion in 2024 and is expected to reach US$ 7.33 billion by 2032, growing at a CAGR of 6.8 % during the forecast period 2025-2032.

The global iron deficiency anemia (IDA) market encompasses the sector dedicated to the diagnosis, treatment, and management of iron deficiency anemia, a condition characterized by inadequate iron levels in the body. This deficiency leads to decreased hemoglobin production and impaired oxygen transport throughout the body. The market includes various therapies, such as oral and parenteral iron supplements, diagnostic tools, and healthcare services aimed at addressing this widespread health issue.

Iron deficiency anemia occurs when the body lacks sufficient iron to produce adequate hemoglobin, which is the protein in red blood cells responsible for carrying oxygen. This condition can manifest through symptoms such as fatigue, weakness, pale skin, and shortness of breath. It is particularly prevalent among vulnerable populations, including women of reproductive age, children, and individuals with chronic illnesses. These factors have driven the global iron deficiency anemia market expansion.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Iron Deficiency Anemia

The increasing prevalence of iron deficiency anemia (IDA) serves as a significant driver for the global iron deficiency anemia market, impacting its growth and evolution. Insufficient dietary iron intake remains a primary cause of IDA. Many populations, particularly in developing regions, lack access to iron-rich foods, leading to increased cases of anemia. Poor dietary habits that do not prioritize iron sources further contribute to the rising prevalence.

According to the National Center for Biotechnology Information (NCBI) research study data in January 2022, the World Health Organization (WHO) has recognized iron deficiency anemia (IDA) as the most prevalent nutritional deficiency globally, affecting approximately 30% of the population. While IDA is particularly common among children and women, adult men are also at risk, especially depending on their socioeconomic status and health conditions.

The primary causes of IDA include gastrointestinal (GI) bleeding and menstruation in women, but decreased dietary iron intake and absorption also significantly contribute to the condition. IDA affects a substantial portion of the global population, with estimates suggesting that around 1.92 billion people were anemic in 2021. This includes a notable prevalence among women of reproductive age and young children, particularly in regions like sub-Saharan Africa and South Asia.

Furthermore, key players in the industry initiatives and product launches that would drive this global iron deficiency anemia market growth. For instance, In November 2022, the Kerala government implemented significant measures to address iron deficiency anemia (IDA) among women by developing a comprehensive plan aimed at sustaining hemoglobin (Hb) levels at 12 mg/dL. This initiative comes in response to concerning findings from the National Family Health Survey (NFHS-5), which revealed that approximately 57% of women aged 15 to 49 in India are anemic, with even higher rates observed in rural areas.

Also, in June 2023, the U.S. Food and Drug Administration (FDA) approved ferric carboxymaltose injection, marketed as Injectafer, for the treatment of iron deficiency in adult patients with heart failure. This approval is particularly significant as it establishes Injectafer as the first and only intravenous (IV) iron replacement therapy specifically indicated for this patient population. All these factors demand the global iron deficiency anemia market.

Moreover, the rising demand for the growth of untapped emerging markets contributes to the global iron deficiency anemia market expansion.

Side Effects Associated with Therapies

Iron deficiency anemia (IDA) poses a significant global health challenge, and the market for its therapies is shaped by various factors, particularly the side effects associated with treatment options. Understanding these side effects is essential for improving patient compliance and ensuring effective treatment strategies.

Oral iron supplements are widely used but frequently lead to gastrointestinal side effects that can limit their effectiveness. Common adverse effects include nausea, constipation, diarrhea, abdominal discomfort, and dark-colored stools. These gastrointestinal issues contribute to poor adherence, with studies indicating that up to 50% of patients may discontinue therapy due to such side effects.

Intravenous (IV) iron therapies, such as ferric carboxymaltose and iron sucrose, serve as alternatives for patients intolerant to oral iron. Allergic reactions, although rare, can necessitate administration in a controlled environment. Thus, the above factors could be limiting the global iron deficiency anemia market's potential growth.

Segment Analysis

The global iron deficiency anemia market is segmented based on therapy type, age group, end-user, and region.

Therapy Type:

The parenteral iron therapy segment is expected to dominate the global iron deficiency anemia market share

The parenteral iron therapy segment holds a major portion of the global iron deficiency anemia market share and is expected to continue to hold a significant portion of the global iron deficiency anemia market share during the forecast period.

The parenteral iron therapy segment is integral to the global iron deficiency anemia (IDA) market, particularly for patients who cannot tolerate oral iron supplements. This segment encompasses several key products including ferric carboxymaltose, ferumoxytol, iron sucrose, and iron dextran. Each of these therapies has distinct characteristics and implications for the market.

Ferric carboxymaltose is a modern intravenous iron formulation designed for rapid administration and higher dosing in a single session. It is especially beneficial for patients with chronic kidney disease or those undergoing dialysis. Ferumoxytol is another intravenous iron therapy notable for its unique formulation that allows for rapid infusion without requiring test doses.

Iron Sucrose is a well-established intravenous iron therapy frequently used in patients with chronic kidney disease. Iron Dextran is one of the earliest intravenous iron formulations. While effective, it requires careful administration due to potential allergic reactions.

Furthermore, key players in the industry product launches would drive this segment's growth in the global iron deficiency anemia market. For instance, In November 2024, Cadila Pharmaceuticals launched Militol, an iron supplement specifically designed to address the pressing issue of iron deficiency in India. These factors have solidified the segment's position in the global iron deficiency anemia market.

Geographical Analysis

North America is expected to hold a significant position in the global iron deficiency anemia market share

North America holds a substantial position in the global iron deficiency anemia market and is expected to hold most of the market share.

Iron deficiency anemia remains one of the most common blood disorders in North America, affecting millions. According to the National Heart, Lung, and Blood Institute, over 3 million Americans are diagnosed with anemia, significantly increasing the demand for effective treatment options.

There is a growing focus on women's health issues, particularly among pregnant women and those experiencing menstrual disorders. This heightened awareness has led to more frequent screenings and diagnoses of IDA, further contributing to market growth. Innovations in iron therapies, including new formulations and delivery methods, have enhanced treatment efficacy and safety profiles. Parenteral iron therapies such as Ferric carboxymaltose and Ferumoxytol are gaining traction due to their rapid administration capabilities and reduced risk of allergic reactions.

Increased investment in healthcare infrastructure supports the adoption of advanced therapies for IDA. This includes funding for research and development that enhances available treatment options for patients. Various government programs aimed at reducing the burden of anemia contribute to market expansion. These initiatives often emphasize education, screening programs, and subsidized treatments for vulnerable populations.

Furthermore, key players in the industry have innovative product launches and approvals that would drive this global iron deficiency anemia market growth. For instance, in October 2024, Seaford Pharmaceuticals launched the "Iron Will" awareness campaign aimed at combating iron deficiency and iron deficiency anemia (IDA) in Canada. This national initiative seeks to educate Canadians about the critical role of iron in overall health and provide practical solutions to address iron deficiency, particularly among vulnerable populations.

Also, in August 2024, Kye Pharmaceuticals announced the approval of ACCRUFeR (ferric maltol) in Canada for the treatment of iron deficiency anemia (IDA) in adult patients. This marks a significant milestone as ACCRUFeR becomes the first prescription-only oral iron therapy approved by Health Canada, specifically indicated for adults who are unresponsive to or intolerant of other oral iron preparations. Thus, the above factors are consolidating the region's position as a dominant force in the global iron deficiency anemia market.

Asia Pacific is growing at the fastest pace in the global iron deficiency anemia market share

Asia Pacific holds the fastest pace in the global iron deficiency anemia market and is expected to hold most of the market share. Iron deficiency poses a significant public health challenge in India, affecting nearly 60% of women and 25% of men, as highlighted by the National Family Health Survey (NFHS-5). The prevalence of iron deficiency anemia is particularly alarming among women of reproductive age, with approximately 57% affected. This deficiency can lead to a range of health issues, including fatigue, impaired cognitive function, weakened immunity, and ultimately, anemia.

To address these risks associated with iron deficiency, Militol has been developed to support optimal iron levels in the body. By targeting these common health concerns, Militol aims to improve overall well-being and prevent the adverse effects linked to inadequate iron intake.

Furthermore, major players in the industry's key initiatives propel this global iron deficiency anemia market growth. For instance, in February 2024, Emcure Pharmaceuticals introduced the 'Unmask Anemia' initiative, designed to assist women in assessing their risk of iron deficiency anemia (IDA) through a straightforward online self-test. This initiative is particularly vital as iron deficiency is one of the leading causes of anemia, and Indian women have the highest prevalence of this condition globally. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global iron deficiency anemia market.

Competitive Landscape

The major global players in the iron deficiency anemia market include Daiichi Sankyo, Inc., Covis Pharma GmbH., Akebia Therapeutics, Inc., PHARMACOSMOS A/S, AbbVie., Shield Therapeutics plc, GSK plc, Rockwell Medical, Inc., Kye Pharmaceuticals, Inc., and Cadila Pharmaceuticals among others.

Key Developments

• In October 2024, P&G Health India, in partnership with the Federation of Obstetric and Gynaecological Societies of India (FOGSI), launched the '12 Ka Naara' campaign to combat the prevalent issue of iron deficiency anemia (IDA) in India. This initiative is particularly important given the alarming data from the National Family Health Survey (NFHS-5), which reveals that around 57% of Indian women suffer from anemia, often remaining unaware of their condition until it becomes severe.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global iron deficiency anemia market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Therapy Type
• 3.2. Snippet by Age Group
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Prevalence of Iron Deficiency Anemia
  • 4.1.2. Restraints
    • 4.1.2.1. Side Effects Associated with Therapies
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Therapy Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 6.1.2. Market Attractiveness Index, By Therapy Type
• 6.2. Oral Iron Therapy*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Ferrous Sulfate
  • 6.2.4. Ferrous Gluconate
  • 6.2.5. Ferrous Fumarate
  • 6.2.6. Polysaccharide Iron Complex
• 6.3. Parenteral Iron Therapy
  • 6.3.1. Ferric carboxymaltose
  • 6.3.2. Ferumoxytol
  • 6.3.3. Iron Sucrose
  • 6.3.4. Iron Dextran
• 6.4. Red Blood Cell Transfusion
• 6.5. Others

7. By Age Group

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 7.1.2. Market Attractiveness Index, By Age Group
• 7.2. Adults*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Pediatric
• 7.4. Geriatric

8. By End-User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.1.2. Market Attractiveness Index, By End-User
• 8.2. Hospitals *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Specilaty Clinics
• 8.4. Homecare Settings

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Daiichi Sankyo, Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio
    • 11.1.2.1. Product Description
    • 11.1.2.2. Product Key Performance Indicators (KPIs)
    • 11.1.2.3. Historic and Forecasted Product Sales
    • 11.1.2.4. Product Sales Volume
  • 11.1.3. Financial Overview
    • 11.1.3.1. Company Revenue's
    • 11.1.3.2. Geographical Revenue Shares
    • 11.1.3.3. Revenue Forecasts
  • 11.1.4. Key Developments
    • 11.1.4.1. Mergers & Acquisitions
    • 11.1.4.2. Key Product Development Activities
    • 11.1.4.3. Regulatory Approvals etc.
  • 11.1.5. SWOT Analysis
• 11.2. Covis Pharma GmbH.
• 11.3. Akebia Therapeutics, Inc.
• 11.4. PHARMACOSMOS A/S
• 11.5. AbbVie.
• 11.6. Shield Therapeutics plc
• 11.7. GSK plc
• 11.8. Rockwell Medical, Inc.
• 11.9. Kye Pharmaceuticals, Inc.
• 11.10. Cadila Pharmaceuticals

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us